193 related articles for article (PubMed ID: 23138323)
1. [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)].
Takahashi Y; Kimura S; Okano M
Nihon Yakurigaku Zasshi; 2012 Nov; 140(5):235-43. PubMed ID: 23138323
[No Abstract] [Full Text] [Related]
2. Azacitidine.
Issa JP; Kantarjian HM; Kirkpatrick P
Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567
[No Abstract] [Full Text] [Related]
3. Azacitidine.
Issa JP; Kantarjian H
Nat Rev Drug Discov; 2005 May; Suppl():S6-7. PubMed ID: 15962522
[TBL] [Abstract][Full Text] [Related]
4. Advances in myelodysplastic syndrome: nursing implications of azacitidine.
Demakos EP; Linebaugh JA
Clin J Oncol Nurs; 2005 Aug; 9(4):417-23. PubMed ID: 16117208
[TBL] [Abstract][Full Text] [Related]
5. Intravenous azacitidine for MDS.
Gore SD
Clin Adv Hematol Oncol; 2007 Mar; 5(3):234. PubMed ID: 17519884
[No Abstract] [Full Text] [Related]
6. Azacitidine and the beginnings of therapeutic epigenetic modulation.
O'Dwyer K; Maslak P
Expert Opin Pharmacother; 2008 Aug; 9(11):1981-6. PubMed ID: 18627335
[TBL] [Abstract][Full Text] [Related]
7. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
Itzykson R; Fenaux P
Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of azacitidine in myelodysplastic syndromes.
Vigil CE; Martin-Santos T; Garcia-Manero G
Drug Des Devel Ther; 2010 Sep; 4():221-9. PubMed ID: 20957213
[TBL] [Abstract][Full Text] [Related]
9. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
10. 5-Azacytidine for the treatment of myelodysplastic syndromes.
Krawczyk J; Keane N; Freeman CL; Swords R; O'Dwyer M; Giles FJ
Expert Opin Pharmacother; 2013 Jun; 14(9):1255-68. PubMed ID: 23621771
[TBL] [Abstract][Full Text] [Related]
11. Azacitine (vidaza) for myelodysplastic syndrome.
Med Lett Drugs Ther; 2005 Jan; 47(1201):11. PubMed ID: 15678015
[TBL] [Abstract][Full Text] [Related]
12. Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma.
Lamprianidou E; Zoulia E; Bernard E; Kordella C; Papoutselis M; Bezirgiannidou Z; Vrachiolias G; Papaemmanuil E; Kotsianidis I
Leuk Lymphoma; 2019 Dec; 60(13):3277-3281. PubMed ID: 31185765
[No Abstract] [Full Text] [Related]
13. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
Adès L; Itzykson R; Fenaux P
Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
[TBL] [Abstract][Full Text] [Related]
14. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
Scott LJ
Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic therapies move into new territory, but how exactly do they work?
Tuma RS
J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
[No Abstract] [Full Text] [Related]
16. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
[TBL] [Abstract][Full Text] [Related]
17. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
Curik N; Burda P; Vargova K; Pospisil V; Belickova M; Vlckova P; Savvulidi F; Necas E; Hajkova H; Haskovec C; Cermak J; Krivjanska M; Trneny M; Laslo P; Jonasova A; Stopka T
Leukemia; 2012 Aug; 26(8):1804-11. PubMed ID: 22343522
[TBL] [Abstract][Full Text] [Related]
18. Azacitidine for the treatment of myelodysplastic syndrome.
Cataldo VD; Cortes J; Quintás-Cardama A
Expert Rev Anticancer Ther; 2009 Jul; 9(7):875-84. PubMed ID: 19589026
[TBL] [Abstract][Full Text] [Related]
19. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
20. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
